Should atezolimab and chemotherapy be considered for stage III dMMR colon cancer with BRAF mutation?

Yes. BRAF V600 mutations were allowed in the ATOMIC study. In fact, BRAF status was a stratification factor. Subgroup analysis showed the benefit of adding Atezolizumab was consistent across the different trial subgroups.